Adam G Kelly1, Robert G Holloway. 1. University of Rochester Medical Center, Department of Neurology, 601 Elmwood Avenue, Box 673, Rochester, NY 14642, USA. Adam_Kelly@urmc.rochester.edu
Abstract
OBJECTIVES: Despite recent trials demonstrating improved functional outcomes in patients with malignant middle cerebral artery ischemic strokes treated with hemicraniectomy, survivors still experience significant stroke-related disability. The value assigned to health states with significant disability varies widely and may influence decisions regarding hemicraniectomy. METHODS: A medical decision analysis was used to evaluate the results of recent hemicraniectomy trials in terms of quality-adjusted life-years. Survival data and probability of various functional outcome states (modified Rankin score 2-3 or 4-5) at 1 year were abstracted from clinical trial data. Utility scores for modified Rankin states were abstracted from literature sources. Sensitivity analyses were performed to study results over a wide range of utility values. All modeling was performed on TreeAge Pro software. RESULTS: The hemicraniectomy treatment pathway was associated with more quality-adjusted life-years over the first year than the medical management pathway (0.414 vs 0.145). Hemicraniectomy remained the preferred option except when the utility associated with the possible outcome states dropped considerably (0.72 to 0.40 for Rankin 2-3, and 0.41 to 0.04 for Rankin 4-5), or when 1-week surgical mortality increased considerably (5% to 67%). CONCLUSIONS: Over a 1-year time horizon, treating patients with malignant middle cerebral artery strokes with hemicraniectomy is associated with more quality-adjusted life-years than medical management alone, except under conditions where patients value possible resultant health states very poorly or surgical mortality is excessively high.
OBJECTIVES: Despite recent trials demonstrating improved functional outcomes in patients with malignant middle cerebral artery ischemic strokes treated with hemicraniectomy, survivors still experience significant stroke-related disability. The value assigned to health states with significant disability varies widely and may influence decisions regarding hemicraniectomy. METHODS: A medical decision analysis was used to evaluate the results of recent hemicraniectomy trials in terms of quality-adjusted life-years. Survival data and probability of various functional outcome states (modified Rankin score 2-3 or 4-5) at 1 year were abstracted from clinical trial data. Utility scores for modified Rankin states were abstracted from literature sources. Sensitivity analyses were performed to study results over a wide range of utility values. All modeling was performed on TreeAge Pro software. RESULTS: The hemicraniectomy treatment pathway was associated with more quality-adjusted life-years over the first year than the medical management pathway (0.414 vs 0.145). Hemicraniectomy remained the preferred option except when the utility associated with the possible outcome states dropped considerably (0.72 to 0.40 for Rankin 2-3, and 0.41 to 0.04 for Rankin 4-5), or when 1-week surgical mortality increased considerably (5% to 67%). CONCLUSIONS: Over a 1-year time horizon, treating patients with malignant middle cerebral artery strokes with hemicraniectomy is associated with more quality-adjusted life-years than medical management alone, except under conditions where patients value possible resultant health states very poorly or surgical mortality is excessively high.
Authors: Pamela W Duncan; Sue Min Lai; Denise Tyler; Subashan Perera; Dean M Reker; Stephanie Studenski Journal: Stroke Date: 2002-11 Impact factor: 7.914
Authors: Georg Leonhardt; Hans Wilhelm; Arnd Doerfler; Christiane E Ehrenfeld; Beate Schoch; Friedhelm Rauhut; Andreas Hufnagel; Hans Christoph Diener Journal: J Neurol Date: 2002-10 Impact factor: 4.849
Authors: Katayoun Vahedi; Jeannette Hofmeijer; Eric Juettler; Eric Vicaut; Bernard George; Ale Algra; G Johan Amelink; Peter Schmiedeck; Stefan Schwab; Peter M Rothwell; Marie-Germaine Bousser; H Bart van der Worp; Werner Hacke Journal: Lancet Neurol Date: 2007-03 Impact factor: 44.182
Authors: Jeannette Hofmeijer; L Jaap Kappelle; Ale Algra; G Johan Amelink; Jan van Gijn; H Bart van der Worp Journal: Lancet Neurol Date: 2009-03-05 Impact factor: 44.182
Authors: Eric Jüttler; Stefan Schwab; Peter Schmiedek; Andreas Unterberg; Michael Hennerici; Johannes Woitzik; Steffen Witte; Ekkehart Jenetzky; Werner Hacke Journal: Stroke Date: 2007-08-09 Impact factor: 7.914